May 14th 2025
Telisotuzumab vedotin (Teliso-V) gained FDA approval as a targeted therapy for patients with advanced non–small cell lung cancer (NSCLC) with high c-Met overexpression, offering new hope.
Watch the series now!
Radiation Oncology’s Role in the Next Chapter of Payment Reform
Amy Ellis: There Was a Big Shift to Telemedicine in Cancer Care Delivery